Paediatric human metapneumovirus infection: Epidemiology, prevention and therapy

Journal of Clinical Virology

Volumn 59, Issue 3, 2014, Pages 141-147

  Principi, Nicola ^a   Esposito, Susanna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiviral therapy; Human metapneumovirus; Monoclonal antibodies; Respiratory infection; Respiratory viruses; Vaccines

Indexed keywords

ANTIVIRAL THERAPY; HUMAN METAPNEUMOVIRUS; MONOCLONAL ANTIBODIES; RESPIRATORY INFECTION; RESPIRATORY VIRUSES; VACCINES;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; VIRAL VACCINES;

EID: 84893967726     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.01.003     Document Type: Review

References (69)

1. van den Hoogen B.G., de Jong J.C., Groen J., Kuiken T., de Groot R., Fouchier R.A., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001, 7:719-724.
2. Papenburg J., Boivin G. The distinguishing features of human metapneumovirus and respiratory syncytial virus. Rev Med Virol 2010, 20:245-260.
3. Leung J., Esper F., Weibel C., Kahn J.S. Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus. J Clin Microbiol 2005, 43:1213-1219.
4. Principi N., Bosis S., Esposito S. Human metapneumovirus in paediatric patients. Clin Microbiol Infect 2006, 12:301-308.
5. Principi N., Esposito S., Bosis S. Human metapneumovirus and lower respiratory tract disease in children. N Engl J Med 2004, 350:1788-1790.
6. Caracciolo S., Minini C., Colombrita D., Rossi D., Miglietti N., Vettore E., et al. Human metapneumovirus infection in young children hospitalized with acute respiratory tract disease: virologic and clinical features. Pediatr Infect Dis J 2008, 27:406-412.
7. Boivin G., De Serres G., Coté S., Gilca R., Abed Y., Rochette L., et al. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 2003, 9:634-640.
8. Døllner H., Risnes K., Radtke A., Nordbø S.A. Outbreak of human metapneumovirus infection in Norwegian children. Pediatr Infect Dis J 2004, 23:436-440.
9. Esper F., Martinello R.A., Boucher D., Weibel C., Ferguson D., Landry M.L., et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis 2004, 189:1388-1396.
10. Freymouth F., Vabret A., Legrand L., Eterradossi N., Lafay-Delaire F., Brouard J., et al. Presence of the new human metapneumovirus in French children with bronchiolitis. Pediatr Infect Dis J 2003, 22:92-94.
11. Gray G.C., Capuano A.W., Setterquist S.F., Erdman D.D., Nobbs N.D., Abed Y., et al. Multi-year study of human metapneumovirus infection at a large US Midwestern medical referral center. J Clin Virol 2006, 37:269-276.
12. Kahn J.S. Epidemiology of human metapneumovirus. Clin Microbiol Rev 2006, 19:546-557.
13. Madhi S.A., Ludewick H., Kuwanda L., van Niekerk N., Cutland C., Klugman K.P. Seasonality, incidence, and repeat human metapneumovirus lower respiratory tract infections in an area with a high prevalence of human immunodeficiency virus type-1 infection. Pediatr Infect Dis J 2007, 26:693-699.
14. McAdam A.J., Hasenbein M.E., Feldman H.A., Cole S.E., Offermann J.T., Riley A.M., et al. Human metapneumovirus in children tested at a tertiary-care hospital. J Infect Dis 2004, 190:20-26.
15. Peiris J.S., Tang W.H., Chan K.H., Khong P.L., Guan Y., Lau Y.L., et al. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 2003, 9:628-633.
16. Williams J.V., Harris P.A., Tollefson S.J., Halburnt-Rush L.L., Pingsterhaus J.M., Edwards K.M., et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004, 350:443-450.
17. Edwards K.M., Zhu Y., Griffin M.R., Weinberg G.A., Hall C.B., Szilagyi P.G., et al. Burden of human metapneumovirus infection in young children. N Engl J Med 2013, 368:633-643. New Vaccine Surveillance Network.
18. Mullins J.A., Erdman D.D., Weinberg G.A., Edwards K., Hall C.B., Walker F.J. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg Infect Dis 2004, 10:700-705.
19. Papenburg J., Hamelin M.È., Ouhoummane N., Carbonneau J., Ouakki M., Raymond F., et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis 2012, 206:178-189.
20. Spaeder M.C., Custer J.W., Bembea M.M., Aganga D.O., Song X., Scafidi S. A multicenter outcomes analysis of children with severe viral respiratory infection due to human metapneumovirus. Pediatr Crit Care Med 2013, 14:268-272.
21. Eggleston H.A., Gunville C.F., Miller J.I., Sontag M.K., Mourani P.M. A comparison of characteristics and outcomes in severe human metapneumovirus and respiratory syncytial virus infections in children treated in an intensive care unit. Pediatr Infect Dis J 2013, (Epub June 27).
22. Hahn A., Wang W., Jaggi P., Dvorchik I., Ramilo O., Koranyi K., et al. Human metapneumovirus infections are associated with severe morbidity in hospitalized children of all ages. Epidemiol Infect 2013, 141:2213-2223.
23. Williams J.V., Martino R., Rabella N., Otegui M., Parody R., Heck J.M., et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005, 192:1061-1065.
24. Englund J.A., Boeckh M., Kuypers J., Nichols W.G., Hackman R.C., Morrow R.A., et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006, 144:344-349.
25. Shachor-Meyouhas Y., Ben-Barak A., Kassis I. Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (hMPV) in immune compromised child. Pediatr Blood Cancer 2011, 57:350-351.
26. Dokos C., Masjosthusmann K., Rellensmann G., Werner C., Schuler-Lüttmann S., Schiborr M., et al. Fatal human metapneumovirus infection following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2013, 15:E97-E101.
27. Bosis S., Esposito S., Osterhaus A.D., Tremolati E., Begliatti E., Tagliabue C., et al. Association between high nasopharyngeal viral load and disease severity in children with human metapneumovirus infection. J Clin Virol 2008, 42:286-290.
28. Feuillet F., Lina B., Rosa-Calatrava M., Boivin G. Ten years of human metapneumovirus research. J Clin Virol 2012, 53:97-105.
29. Huck B., Egger M., Bertz H., Peyerl-Hoffman G., Kern W.V., Neumann-Haefelin D., et al. Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. J Clin Microbiol 2006, 44:2300-2303.
30. Papenburg J., Carbonneau J., Isabel S., Bergeron M.G., Williams J.V., De Serres G., et al. Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade. J Clin Virol 2013, 58:541-547.
31. Yang C.F., Wang C.K., Tollefson S.J., Lintao L.D., Liem A., Chu M., et al. Human metapneumovirus G protein is highly conserved within but not between genetic lineages. Arch Virol 2013, 158:1245-1252.
32. Skiadopoulos M.H., Biacchesi S., Buchholz U.J., Riggs J.M., Surman S.R., Amaro-Carambot E., et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004, 78:6927-6937.
33. van den Hoogen B.G., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002, 295:119-132.
34. van den Hoogen B.G., Herfst S., de Graaf M., Sprong L., van Lavieren R., van Amerongen G., et al. Experimental infection of macaques with human metapneumovirus induces transient protective immunity. J Gen Virol 2007, 88:1251-1259.
35. Yim K.C., Cragin R.P., Boukhvalova M.S., Blanco J.C., Hamlin M.E., Boivin G., et al. Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine 2007, 25:5034-5040.
36. de Swart R.L., van den Hoogen B.G., Kuiken T., Herfst S., van Amerongen G., Yüksel S., et al. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 2007, 25:8518-8528.
37. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
38. Tang R.S., Mahmood K., Macphail M., Guzzetta J.M., Haller A.A., Liu H., et al. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine 2005, 23:1657-1667.
39. Biacchesi S., Skiadopoulos M.H., Yang L., Lamirande E.W., Tran K.C., Murphy B.R., et al. Recombinant human metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol 2004, 78:12877-12887.
40. Biacchesi S., Pham Q.N., Skiadopoulos M.H., Murphy B.R., Collins P.L., Buchholz U.J. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol 2005, 79:12608-12613.
41. Buchholz U.J., Biacchesi S., Pham Q.N., Tran K.C., Yang L., Luongo C.L., et al. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol 2005, 79:6588-6597.
42. Herfst S., de Graaf M., Schrauwen E.J., Sprong L., Hussain K., van den Hoogen B.G., et al. Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters. J Gen Virol 2008, 89:1553-1562.
43. Herfst S., Schrauwen E.J., de Graaf M., van Amerongen G., van den Hoogen B.G., de Swart R.L. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine 2008, 26:4224-4230.
44. Pham Q.N., Biacchesi S., Skiadopoulos M.H., Murphy B.R., Collins P.L., Buchholz U.J. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus. J Virol 2005, 79:15114-15122.
45. Clinical Trials.Gov evaluation of the immunogenicity and safety of a live attenuated human metapneumovirus vaccine. Available at: [accessed 30.10.13]. http://clinicaltrials.gov/show/NCT01255410.
46. Cseke G., Wright D.W., Tollefson S.J., Johnson J.E., Crowe J.E., Williams J.V. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol 2007, 81:698-707.
47. Lévy C., Aerts L., Hamelin M.È., Granier C., Szécsi J., Lavillette D., et al. Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. Vaccine 2013, 31:2778-2785.
48. Meissner H.C., Long S.S. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003, 112:1447-1452.
49. Wyde P.R., Moylett E.H., Chetty S.N., Jewell A., Bowlin T.L., Piedra P.A. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays. Antivir Res 2004, 63:51-59.
50. Ulbrandt N.D., Ji H., Patel N.K., Riggs J.M., Brewah Y.A., Ready S., et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol 2006, 80:7799-7806.
51. Ulbrandt N.D., Ji H., Patel N.K., Barnes A.S., Wilson S., Kiener P.A., et al. Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. J Gen Virol 2008, 89:3113-3118.
52. Hamelin M.E., Couture C., Sackett M., Kiener P., Suzich J., Ulbrandt N., et al. The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. Antivir Ther 2008, 13:39-46.
53. Hamelin M.E., Gagnon C., Prince G.A., Kiener P., Suzich J., Ulbrandt N., et al. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antivir Res 2010, 88:31-37.
54. Corti D., Bianchi S., Vanzetta F., Minola A., Perez L., Agatic G., et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 2013, 501:439-443.
55. Empey K.M., Peebles R.S., Kolls J.K. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010, 50:1258-1267.
56. Hamelin M.E., Prince G.A., Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 2006, 50:774-777.
57. Sookoian S., Castano G., Flichman D., Cello J. Effect of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. Ann Hepatol 2004, 3:104-107.
58. Ventre K., Randolph A.G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007, CD000181.
59. Nichols W.G., Peck Campbell A.J., Boeckh M. Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin Microbiol Rev 2008, 21:274-290.
60. Preston S.L., Drusano G.L., Glue P., Nash J., Gupta S.K., McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999, 43:2451-2456.
61. Park S.Y., Baek S., Lee S.O., Choi S.H., Kim Y.S., Woo J.H. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. Antimicrob Agents Chemother 2013, 57:983-989.
62. Raza K., Ismailjee S.B., Crespo M., Studer S.M., Sanghavi S., Paterson D.L., et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007, 26:862-864.
63. Kamble R.T., Bollard C., Demmler G. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant 2007, 40:699-700.
64. Shahda S., Carlos W.G., Kiel P.J., Khan Ba Hage C.A. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis 2011, 13:324-328.
65. Bonney D., Razali H., Turner A., Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol 2009, 145:665-678.
66. Kitanovski L., Kopriva S., Pokorn M., Dolničar M.B., Rajić V., Stefanović M., et al. Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol 2013, 35:e311-e313.
67. Deffrasnes C., Hamelin M.E., Prince G.A., Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother 2008, 52:279-287.
68. Deffrasnes C., Cavanagh M.H., Goyette N., Cui K., Ge Q., Seth S., et al. Inhibition of human metapneumovirus replication by small interfering RNA. Antivir Ther 2008, 13:821-832.
69. Darniot M., Schildgen V., Schildgen O., Sproat B., Kleines M., Ditt V., et al. RNA interference in vitro and in vivo using DsiRNA targeting the nucleocapsid N mRNA of human metapneumovirus. Antivir Res 2012, 93:364-373.